img

BHK Rabies Vaccine Market By Strain Type (Type A, Type C, Type O), By Application (Pre-Exposure Prophylaxis, Post-Exposure Prophylaxis), & Region For 2024-2031


Published on: 2024-08-07 | No of Pages : 320 | Industry : latest updates trending Report

Publisher : MIR | Format : PDF&Excel

BHK Rabies Vaccine Market By Strain Type (Type A, Type C, Type O), By Application (Pre-Exposure Prophylaxis, Post-Exposure Prophylaxis), & Region For 2024-2031

BHK Rabies Vaccine Market Valuation – 2024-2031

The increasing prevalence of rabies worldwide is driving up demand for effective vaccinations, which is why the size of the BHK Rabies Vaccine Market exceeded USD 20.3 Billion in 2023 and is expected to reach USD 35.3 Billion by 2031. Growing awareness of the deadly implications of rabies is pushing governments and healthcare organizations to prioritize rabies prevention through mass vaccination programs, which is significantly fueling the market’s rise. The focus on animal immunization is assisting in the market’s growth, which is anticipated to increase at a CAGR of 7.90% between 2024 and 2031 because pets and livestock are important sources of rabies.

BHK Rabies Vaccine MarketDefinition/ Overview

BHK vaccine is the one form of vaccination used to prevent and manage rabies. Rabies is a deadly virus that infects animals, including humans, in their central nervous systems. Its source is the baby hamster kidney (BHK) cell line, which serves as a medium for the rabies virus strain that is employed in the vaccination. Inactivated or attenuated strains of the rabies virus are injected into the body by BHK rabies vaccines, which then cause an immunological response that results in the production of antibodies against the virus. If a person is exposed to the rabies virus again in the future, this acquired immunity helps shield them from contracting the disease.

These vaccinations are frequently used to prevent rabies before exposure as well as after exposure. Pre-exposure prophylaxis includes giving the vaccination to anyone who could be exposed, such as lab workers, veterinary professionals, and tourists visiting rabies-endemic regions. Those who have been bitten or scratched by an animal that may be rabid are administered post-exposure prophylaxis, which offers prompt protection and stops the illness from spreading. BHK rabies vaccinations are essential to rabies prevention and control efforts, particularly in regions where the illness is common. They are a vital instrument for safeguarding the health of people and animals, lessening the impact of this fatal illness, and advancing the global aim of eradicating rabies.

What's inside a
industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Could the Increasing Incidence of Rabies Drive up the Demand for BHK Rabies Vaccines?

The rising global prevalence of rabies is a major factor driving the growth of the BHK Rabies Vaccine Market. Rabies is a deadly virus that poses a serious risk to public health, especially in underdeveloped nations where access to effective preventative measures is restricted.Governments and healthcare groups are making rabies prevention through mass vaccination campaigns a priority as public knowledge of the disease’s devastating effects grows. To immunize at-risk people and contribute to the global decline in rabies incidents, the distribution of BHK rabies vaccinations is essential to these efforts. Regulatory bodies are providing support and incentives to vaccine manufacturers, encouraging investment in the development and commercialization of BHK rabies vaccines. This regulatory support is fostering a conducive environment for market growth.

In addition, the growing emphasis on animal welfare and the necessity to avoid zoonotic illnesses are driving the acceptance of BHK rabies vaccinations in veterinary clinics. Animal vaccination is an essential part of rabies management programs since pets and livestock are known to be possible carriers of the disease. Concerns about rabies’ effects on animal populations and the possibility of zoonotic transmission to humans are what’s driving this greater emphasis on animal immunization. The BHK Rabies Vaccine Market is expected to increase overall as a result of the large reduction in the risk of rabies transmission that can be achieved by vaccination, especially for animals that have close contact with people. Moreover, advancements in vaccine technology and manufacturing processes are contributing to market expansion. Continuous research and development efforts are leading to the development of more efficient and cost-effective BHK rabies vaccines. These technological advancements are improving the quality and accessibility of vaccines, driving their adoption and usage. In conclusion, the growth of the BHK Rabies Vaccine Market is driven by increasing awareness, government initiatives, rising incidence of rabies, technological advancements, expanding animal healthcare sector, and favorable regulations.

Is the Lack of Awareness Regarding Rabies Prevention Hampering the Growth of the BHK Rabies Vaccine Market?

The BHK Rabies Vaccine Market has bright future possibilities, but some obstacles can prevent it from growing. The lack of knowledge about the significance of rabies prevention is a major obstacle, especially in isolated and rural regions with little access to medical facilities and educational resources. Misconceptions and cultural beliefs about rabies and how it spreads are common in many areas, which makes people reluctant to seek early medical attention or preventive measures. This ignorance might lead to a delay in obtaining post-exposure prophylaxis, raising the possibility of mortality from rabies and decreasing the need for vaccinations. There are still issues with the accessibility and availability of reasonably priced rabies vaccinations in environments with limited resources. Widespread adoption is hindered by the high expenses of immunization programs as well as the logistical difficulties of storing and distributing vaccinations in distant locations.

The prevalence of rabies continues to be a serious public health problem even with the availability of effective post-exposure prophylaxis, especially in developing and undeveloped areas with limited access to medical services. This urgent requirement is driving investments in the discovery and manufacturing of high-quality rabies vaccines, which is driving up the BHK Rabies Vaccine Market. BHK rabies vaccines may be priced out of reach for certain demographic groups, especially in low-income or developing countries where rabies is prevalent. The high cost of these vaccines relative to household income levels can deter individuals from purchasing them, resulting in reduced sales volume.

Category-Wise Acumens

What Factors Contribute to the Dominance of the Type A Strain in the BHK Rabies Vaccine Market?

Due to its widespread acceptability and effectiveness in preventing rabies, the type A strain of the vaccine is expected to dominate the BHK Rabies Vaccine Market. This strain, which is a variant of the Pasteur virus, is favored by medical practitioners worldwide due to its well-established safety profile and dependability. The type A strain has proven its capacity to trigger a strong immune response against the rabies virus via extensive testing and clinical studies. Its proven ability to prevent rabies infections has played a major role in its widespread acceptance in immunization programs around the globe. Its versatility in terms of production platforms—such as BHK (baby hamster kidney) cell culture systems—has made it easier to manufacture and distribute on a broad scale. This has further contributed to its commercial domination by enabling the creation of accessible and reasonably priced BHK rabies vaccines based on the type A strain.

Furthermore, the type A strain’s extensive usage in pre- and post-exposure prophylactic regimens can be attributed to healthcare practitioners’ improved trust in its administration stemming from their knowledge and expertise with it. The BHK rabies vaccinations, which are based on the type A strain, are well-positioned to fulfill the growing need for dependable and efficient rabies vaccinations by leveraging their known safety profile and shown performance. Its compatibility with existing vaccination protocols and production processes fosters its widespread use. Vaccine manufacturers prioritize strains that can be seamlessly integrated into their manufacturing pipelines and administered using established vaccination schedules. The type A strain’s compatibility reduces production costs and logistical complexities, making it an attractive option for vaccine manufacturers and healthcare providers alike.

Will the Rising Importance of Pre-Exposure Prophylaxis Boost the Adoption of BHK Rabies Vaccines?

The pre-exposure prophylaxis segment of the BHK Rabies Vaccine Market is anticipated to develop at a substantial rate because of the growing focus on preventative methods against rabies infection. Pre-exposure prophylaxis is immunizing people against rabies who are at high risk of exposure, such as veterinarians, animal handlers, workers in laboratories, and tourists visiting areas where rabies is endemic. Pre-exposure prophylaxis is becoming more and more popular since it is successful in boosting immunity, which makes post-exposure therapy more effective and can be administered more quickly in the event of probable rabies exposure. This preventive measure is not only lowering the chance of contracting rabies but also streamlining the post-exposure protocol to make it easier to follow and less expensive.

Because of their strong immunogenicity and good safety profile, BHK rabies vaccines—which are generated from the baby hamster kidney cell culture system—have become the recommended option for pre-exposure prophylaxis. For anyone who could be in danger of coming into contact with the rabies virus at work or during leisure activities, these vaccinations provide a dependable and well-tolerated choice. The demand for BHK rabies vaccines is also being driven by the increased understanding of the value of pre-exposure prophylaxis among medical practitioners and occupational health authorities. Pre-exposure vaccination has become increasingly important due to strict workplace safety norms and regulations across a range of sectors, which has fueled the expansion of this market segment. The demand for BHK rabies vaccines is anticipated to soar, establishing this category as a major driver in the overall market as the emphasis on preventive measures increases and pre-exposure prophylaxis is recognized as an essential technique in rabies reduction.

Gain Access to Carbon Footprint Management Market Report Methodology

Country/Region-wise Acumens

How has the High Rabies Infection Rate and Growing Emphasis on Disease Prevention in Asia Pacific Impacted the Demand for BHK Rabies Vaccine?

The Asia Pacific region is developing as the leading market for BHK rabies vaccines due to the high frequency of rabies infections and the increasing focus on effective disease-preventive strategies. Asia accounts for over 59% of the world’s rabies deaths, according to the World Health Organization (WHO), highlighting the critical need for extensive immunization campaigns in this area. India bears a disproportionate amount of the rabies burden, with an estimated 20,000 fatalities from the disease each year. The Indian government launched widespread immunization efforts in response to this worrying trend, which has increased demand for BHK rabies vaccines in the area. In the same vein, China, Bangladesh, and Indonesia have all seen an increase in rabies incidences, which has fueled the need for BHK rabies vaccines as a preventive step. The danger of rabies transmission has increased in many nations due to rising urbanization and the growth of human-animal interfaces, which has made the deployment of comprehensive vaccination programs necessary.

Additionally, the growing recognition of the value of rabies protection among medical experts and the general population has been a major factor in increasing the demand for BHK rabies vaccines in Asia Pacific. Governments and non-governmental groups have conducted extensive information programs to promote vaccination, especially in rural and underserved regions where there is a higher risk of rabies exposure. The increasing trend of pet ownership in the Asia Pacific area has also aided the market expansion of BHK rabies vaccines. Pet owners are starting to realize how important it is to vaccinate their animals against rabies, which is driving up demand for these vaccinations. The demand for BHK rabies vaccines in the Asia Pacific is predicted to continue rising due to the region’s high disease burden, emphasis on enhancing healthcare infrastructure, and access to necessary vaccines, and these factors together with the region’s focus on making the vaccines a life-saving option.

What Drives the Demand for BHK Rabies Vaccines in North America, and How Does the Region’s Healthcare System and Economic Status Affect their Adoption?

The demand for BHK rabies vaccines in North America is primarily driven by several factors. The region’s well-established healthcare system and strict laws controlling rabies prevention and control methods are to blame for this high demand. Strict policies and procedures are in place in the US and Canada to protect those who are most likely to come into contact with the rabies virus, including lab workers, animal control officials, and veterinarians. These restrictions drive the use of BHK Rabies vaccinations in the region by requiring pre-exposure prophylaxis with rabies vaccinations.

Furthermore, the public’s and healthcare professionals’ high levels of awareness of the significance of rabies prevention contribute to the ongoing need for these vaccinations. In public health campaigns and educational activities, vaccine promotion has been essential, especially for those with work or recreational exposure hazards. The extensive supply chain networks and well-equipped medical institutions found in North America contribute to the easy accessibility and dissemination of BHK rabies vaccines. This guarantees that medical professionals will have easy access to these vaccinations, allowing them to give them to people who need them on time. In addition, the robust economic conditions and high buying power of the region have led to the increased adoption of preventative healthcare measures, such as rabies vaccination. the region’s relatively high economic status allows for greater affordability and accessibility of BHK rabies vaccines. Public and private healthcare systems, along with insurance coverage, ensure that vaccines are accessible to a large portion of the population. The willingness of North American consumers to spend money on high-quality medical supplies is another factor boosting the use of BHK rabies vaccines.

Competitive Landscape

The BHK Rabies Vaccine Market is characterized by a diverse landscape of prominent players, including both established pharmaceutical companies and emerging biotechnology firms. These players are continuously striving to develop and commercialize innovative and effective rabies vaccines to meet the growing global demand. The market is driven by technological advancements, strategic partnerships, and a commitment to improving public health.

Some of the prominent players operating in the BHK Rabies Vaccine Market include

Sanofi Pasteur, GSK (GlaxoSmithKline), Merck & Co., Cadila Pharmaceuticals, Bharat Biotech, Serum Institute of India, Changsheng Life Sciences, Chengdu Kanghua Biological Products, Poonawalla Biotech, Zydus Cadila, Biological E. Limited, Novavax.

Latest Developments

  • In April 2022, Cadila Pharmaceuticals, a pharmaceutical company, launched the world’s first novel three-dose rabies vaccine, ThRabis, using Virus-Like Particle technology (VLP). This vaccine is prepared by using VLPs that self-assemble from the recombinant G protein, providing a safer and more effective alternative to traditional vaccines.

Report Scope

REPORT ATTRIBUTESDETAILS
STUDY PERIOD

2018-2031

Growth Rate

CAGR of ~7.90% from 2024 to 2031

Base Year for Valuation

2023

Historical Period

2018-2022

Forecast Period

2024-2031

Quantitative Units

Value in USD Billion

Report Coverage

Historical and Forecast Revenue Forecast, Historical and Forecast Volume, Growth Factors, Trends, Competitive Landscape, Key Players, Segmentation Analysis

Segments Covered
  • Strain Type
  • Application
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Key Players

Sanofi Pasteur, GSK (GlaxoSmithKline), Merck & Co., Cadila Pharmaceuticals, Bharat Biotech, Serum Institute of India, Changsheng Life Sciences.

Customization

Report customization along with purchase available upon request

BHK Rabies Vaccine Market, By Category

Strain Type

  • Type A
  • Type C
  • Type O
  • Others

Application

  • Pre-Exposure Prophylaxis
  • Post-Exposure Prophylaxis

Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Ext

Table of Content

To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )
To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )